Dr. Chung received a 5 year NIH U19 award (U19-AI142762) entitled“Center of Excellence for Encephalitic Alphavirus Therapeutics”, as MPI/Project leader.

Dr. Egilmez was awarded a two year Idea Development grant (LC180086)  from the DOD Lung Cancer  Research Program for a project entitled “Overcoming Anti-PD-1 Resistance in Lung Cancer” (PI) and a 3 year R44 award from the NIH (R44-DK117687) entitled “IL-10NanoCap for Therapy of Familial Adenomatous Polyposis” (MPI).

Dr. Shirwan was awarded a two-year NIH R21 grant (R21-AI147677) entitled “Establishing immunoprivileged scaffolds for transplantation of immature beta cells.

Dr. Matt Lawrenz is co-investigator on an NIH STTR (R41-AI142726) grant entitled “Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia” with a subaward to his laboratory.  The project period is 4/1/2019 – 3/31/2020.